Menopause modulates the circulating metabolome: evidence from a prospective cohort study

Jari E. Karppinen¹, Timo Törmäkangas², Urho M. Kujala¹, Sarianna Sipilä², Jari Laukkanen^{1,3,4}, Pauliina Aukee⁵, Vuokko Kovanen² and Eija K. Laakkonen²

The work was performed at Gerontology Research Center and Faculty of Sport and Health Sciences, University of Jyväskylä, Jyväskylä, Finland.

1 Faculty of Sport and Health Sciences, University of Jyväskylä, Jyväskylä, Finland.

2 Gerontology Research Center and Faculty of Sport and Health Sciences, University of Jyväskylä, Jyväskylä, Finland.

3 Department of Internal Medicine, Central Finland Health Care District, Jyväskylä, Finland.

4 Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.

5 Department of Obstetrics and Gynecology, Pelvic Floor Research and Therapy Unit, Central Finland Health Care District, Jyväskylä, Finland.

Corresponding author: Eija K. Laakkonen, eija.k.laakkonen@jyu.fi

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

Aims We studied the changes in the circulating metabolome and their relation to the menopausal hormonal shift in 17 β -oestradiol and follicle-stimulating hormone levels among women transitioning from perimenopause to early postmenopause.

Methods and Results We analysed longitudinal data from 218 Finnish women, 35 of whom started menopausal hormone therapy during the study. The menopausal transition was monitored with menstrual diaries and serum hormone measurements. The median follow-up was 14 months (interquartile range: 8–20). Serum metabolites were quantified with targeted nuclear magnetic resonance metabolomics. The model results were adjusted for age, follow-up duration, education, lifestyle, and multiple comparisons. Menopause was associated with 84 metabolite measures. The concentration of apoB (0.17 standard deviation [SD], 99.5% confidence interval [CI] 0.03–0.31), VLDL triglycerides (0.25 SD, CI 0.05–0.45) and particles (0.21 SD, CI 0.05–0.36), LDL cholesterol (0.17 SD, CI 0.01–0.34) and particles (0.17 SD, CI 0.03–0.31), HDL triglycerides (0.24 SD, CI 0.02–0.46), glycerol (0.32 SD, CI 0.07–0.58) and leucine increased (0.25 SD, CI 0.02–0.49). Citrate (-0.36 SD, CI -0.57 to -0.14) and 3-hydroxybutyrate concentrations decreased (-0.46 SD, CI -0.75 to -0.17). Most metabolite changes were associated with the menopausal hormonal shift. This explained 10% and 9% of the LDL cholesterol and particle concentration increase, respectively. Menopausal hormone therapy was associated with increased medium-to-large HDL particle count and decreased small-to-medium LDL particle and glycine concentration.

Conclusions Menopause is associated with proatherogenic circulating metabolome alterations. Female sex hormones levels are connected to the alterations, highlighting their impact on women's cardiovascular health.

Keywords: menopause, hormone replacement therapy, cardiovascular diseases, metabolomics, oestradiol

‘One-sentence Summary’: Female sex hormone alterations induced by menopause altered the levels of circulating metabolites, leading to a higher risk profile for cardiovascular diseases.

Introduction

Most women face menopause at the age of 48–52 years,¹ resulting from the cessation of ovarian follicular activity and diagnosed 12 months after the final menstrual period.² The characteristic menopausal hormonal shift consists of a decline in 17 β -oestradiol (E2) and a concomitant increase in follicle-stimulating hormone (FSH) levels.¹ Oestrogen-containing menopausal hormone therapy (MHT) alleviates menopausal symptoms and restores systemic E2 without lowering FSH to premenopausal levels.³

Menopause is thought to predispose women to atherosclerotic cardiovascular disease (ACVD) since they develop obstructive coronary artery disease 7–10 years later than men, and this risk rises after menopause.⁴ Also, premature menopause is associated with an increased ACVD risk.⁵ The causality between these phenomena is difficult to prove, as the menopause-driven metabolic changes may predispose women to present ACVD at an older age, making it difficult to distinguish their effects from other ageing-related changes.⁶ Moreover, as it is generally not possible to predict the timing of menopause, establishing appropriate longitudinal study settings is challenging. Perimenopause (the menopausal transition phase) also differs in timing and duration among individuals.¹ Therefore, individual information on menopause progression benefits the investigation of menopausal effects.

Research on clinical biomarkers supports the relationship between menopause and ACVD risk. In longitudinal studies, menopause is associated with increases in circulating triglyceride and low-density lipoprotein (LDL) cholesterol levels. However, the effect of menopause on high-density lipoprotein (HDL) cholesterol concentration and its direction is controversial.^{7–10} The biomarker changes may result directly from the menopausal hormonal shift or indirectly via increased adiposity.¹¹ The role of female sex hormones is strengthened by studies on MHT in postmenopausal women. Oestrogen-only MHT lowers LDL cholesterol

and increases HDL cholesterol concentrations accompanied by a rise in triglyceride levels when administered orally.¹² In combination MHT, the effects on HDL cholesterol are modulated by selected progestogen.¹² MHT may also improve blood glucose regulation,¹³ reflecting broad systemic effects on metabolism.

Compared with clinical methods, metabolomics offer a wider lens to investigate menopausal effects on the circulating metabolome. Two population-level nuclear magnetic resonance (NMR) metabolomics studies on menopause have been conducted. The cross-sectional study by Auro et al.¹⁵ examined associations between age, sex, and menopause and the circulating metabolome in 26 065 Finnish and Estonian individuals, including 10 083 women. Later, Wang et al.¹⁶ investigated cross-sectional associations in the UK among 3 312 women, with 1 492 longitudinal samples taken 2.5 years apart. Their results were similar; menopause was associated with a proatherogenic shift in lipoprotein measurements and non-lipid metabolites, such as amino acids.^{15,16} Both studies relied on self-reported menopausal status and did not associate the findings to the female sex hormone levels.

Therefore, here, we investigated whether the menopause-related hormonal shift modulates the circulating metabolome in a longitudinal design, where the follow-up of the menopausal transition progression was individualised and monitored with repeated FSH level measurements. The premise was that menopause has an identifiable metabolomic fingerprint resulting from the shift of female sex hormone levels.

Methods

Study design and participants

This study used data from the Estrogenic Regulation of Muscle Apoptosis (ERMA) prospective cohort study¹⁷ and was approved by the ethics committee of the Central Finland Health Care District (KSSHP Dnro 8U/2014). The study complied with the Declaration of Helsinki, and participants gave informed consent.

The recruitment and the first measurements were performed between 2014 and 2015. The follow-up data were collected between 2015 and 2019. The sample was randomly drawn from the Population Information System. An invitation and a prequestionnaire were sent to 6 878 women aged 47–55 living in the Jyväskylä area. The response rate was 47%. Based on the prequestionnaire data, 1 627 women were invited to menopausal status determination. Exclusion criteria were self-reported body mass index $> 35 \text{ kg/m}^2$ and medical conditions or use of medication affecting the ovaries, the hormone or inflammatory profile, or daily functioning. The menopausal status of 1 393 women was determined, and 1 158 women were called to the Health and Sports Laboratory of the University of Jyväskylä for physiological and psychological measurements.

The ERMA study aimed to create a cohort for the investigation of menopausal effects with a minimum influence of ageing. Therefore, 381 perimenopausal women were invited to participate in the longitudinal Core-ERMA study (**Fig. 1**). Women kept a menstrual diary during follow-up and visited the laboratory for the measurement of FSH levels every 3 or 6 months until early postmenopause. The follow-up was scheduled according to the participant's menopausal transition progression.

Of the 381 participants, the follow-up was completed by 234 women. One participant died, and 26 dropped out. Three women reported inconsistent MHT use and 117 women did not reach postmenopause or their menopausal status was uncertain at the last measurement, leading to exclusion. From this study, we excluded 12 women using lipid or

glucose-lowering medication and 4 women diagnosed with cancer. Therefore, the metabolomics analyses were performed for 218 participants, with 35 (15%) starting MHT during follow-up.

Hormone and metabolites profile

Blood samples were collected between 7–10 AM after overnight fasting and processed for serum collection with a standard procedure. The samples were aliquoted and stored at –80 °C until analysis. E2 and FSH levels were measured with IMMULITE 2000 XPi (Siemens Healthcare Diagnostics, UK). Metabolites were analysed with a targeted proton nuclear magnetic resonance (¹H-NMR) spectroscopy platform (Nightingale Health Ltd., Helsinki, Finland; biomarker quantification version 2020).¹⁸ The platform quantifies 250 metabolite measures and 180 were selected as outcomes. The lipoprotein lipid ratios were not included due to the limited sample size and because they were unlikely to provide substantial added value.

Menopausal status and menopausal hormone therapy use

The guidelines Stages of Reproductive Aging Workshop (STRAW) + 10 with slight modifications were used to determine the menopausal status.² Women kept a menstrual diary for 3 months before the first blood sampling. Perimenopausal women were required to have irregular or no menstrual bleeding and FSH levels of 17–30 IU/l. During follow-up, women were determined postmenopausal after two consecutive FSH measurements of > 30 IU/l and at least 6 months of amenorrhea. However, the absence of menses was slightly shorter in 16 participants. The criterion differs from the guidelines where postmenopause begins after 12

months of amenorrhea due to practical limitations. We decided to compromise the length of the follow-up period to maximise the number of women with valid end measurements inside a limited project funding period. The median amenorrhea duration was 8.1 months (interquartile range: 6.5–10.4). The postmenopausal status of 25 participants was determined solely based on FSH levels because of prior hysterectomy ($n = 11$) or ambiguity in menstrual diary reporting ($n = 14$).

MHT was queried at each follow-up meeting, and MHT participants were invited to the last measurement 6 months after the initiation of the treatment to allow the medication to exert its effects. One woman reported starting MHT 17 days before and another participant 2 days before the last measurement. We only classified the former as an MHT user because a 2-day use was unlikely to substantially affect metabolism. Her metabolite levels did not significantly differ from the other participants' levels. Of the 35 MHT starters, 27 used oral products containing either E2-only ($n = 7$), E2 in combination with dydrogesterone ($n = 16$) or norethisterone acetate ($n = 4$). Concerning the E2-only MHT starters, 5 were users of levonorgestrel-releasing intrauterine devices, and 2 did not need progestogen because of past hysterectomy. The rest of the sample ($n = 8$) used transdermal MHT, 7 of whom used E2-gel with a levonorgestrel-releasing intrauterine device and one E2 and norethisterone acetate patches.

Education level, lifestyle factors and body composition

The Method Supplement includes a detailed description of the study covariates. Briefly, the education level (primary, secondary or tertiary) and lifestyle factors were recorded with structured questionnaires. Due to the low number of participants with primary education, primary and secondary were combined in the statistical analyses. Smoking status was

classified as ‘never’, ‘quitter’, or ‘current smoker’. As the number of current smokers was low, dummy variables were created to describe whether the participant had ever smoked and smoked currently. Alcohol use was calculated as portions per week. Physical activity was calculated as metabolic equivalent hours per day (MET-h/d) by assessing the duration, frequency and intensity of leisure-time physical activity and the time spent on active commuting.¹⁹ Use of common foods in Finnish food culture were recorded with a 45-item food-frequency questionnaire and the diet quality was measured with an 11-element diet quality sum score (DQS) adapted from a validated tool,²⁰ where a higher score reflects a healthier diet. Height was measured with a stadiometer at the first measurement. Body mass and body fat percentage were measured with InBody720 (Biospace, Seoul, Korea).

Statistical analyses

The statistical analyses are described in detail in **the Method Supplement**. Questionnaire-based data were missing from 1 participant at the first and 2 participants at the last measurement. We completed the missing values by inspecting participants’ answers from other visits or mean imputation. Metabolite data were nearly complete, and we did not impute the rare missing values. R version 4.0.0 or newer was used for statistical analyses unless stated otherwise.

The primary results are the associations between menopause and metabolite measurements in 183 women experiencing natural menopause, i.e., who did not start MHT during follow-up (**Fig. 1**). Analyses were performed using linear mixed-effect models with random intercept after metabolite Box-Cox transformation and standardisation with respect to the first measurements. The metabolites were treated as outcomes and the menopausal status as exposure. Two adjusted models were built in addition to a crude model. The first adjusted

model (the main study results) included the covariates of age at the first measurement, follow-up duration, education level and lifestyle factors. In the second adjusted model, the body fat percentage (potential mediator between menopause and metabolites) was included as a covariate. The K_{eff} -Šidák correction was used to account for multiple testing.

Two exploratory analyses were performed. First, the direct and indirect associations (via body fat percentage change) between the menopausal hormonal shift and metabolite changes in the women experiencing natural menopause ($n = 183$) were investigated using latent change score modelling. Both E2 and FSH were included in the model simultaneously because this combination better characterises an individual's sex hormone profile as E2 levels fluctuate during perimenopause. The used model (**Method Supplement Fig. 1**) can be seen as an extension of the paired t -test, where change is controlled for metabolite concentrations at the first measurement. The calculated effect sizes are interpreted similarly to squared semi-partial correlations and indicate how much of the metabolite change is explained by the menopausal hormonal shift. Mplus version 7.4 was used to estimate the model parameters. False discovery rate adjustment was used to correct for multiple testing. The association of MHT initiation during follow-up with the metabolite measurements was studied in the whole sample ($N = 218$, $N_{\text{MHT starters}} = 35$) using menopausal status and MHT interaction as the exposure. The model structures and multiple testing corrections were performed as in the primary analysis.

Results

Participant characteristics can be found in **Table 1**. The mean age of participants was 51.7 (SD = 1.9) at the first measurement. Hypertension was the most commonly diagnosed condition in the cohort. Participants did not use lipid-lowering agents, even though more than

half had elevated LDL cholesterol levels (> 3 mmol/l). MHT starters were younger than non-users at the first measurement. Moreover, they had lower FSH levels and systolic/diastolic blood pressure. As for the rest of the variables, the groups showed similar characteristics at the beginning of the study.

The median follow-up duration was 14 months (interquartile range: 8–15), ranging from 4 months to 3.5 years. Expectedly, E2 decreased and FSH increased in women not using MHT during follow-up. Among MHT starters, E2 increased without an apparent change in FSH levels. As for lifestyle factors, alcohol use decreased in both groups and body fat percentage increased by 1% for the total sample with a similar trend in both groups.

Menopause and metabolite associations

In **Results Supplement Table 1**, the absolute metabolite concentrations during the study and the unstandardised metabolite change scores of the 183 women experiencing natural menopause are shown. Menopause was associated with a statistically significant change in 85 metabolite measures (**Result Supplement Table 3**; the key findings are summarised in **Fig. 2**). The apolipoprotein B (apoB)-containing particle count increased by 0.17 SD (99.95% confidence interval [CI] 0.03–0.31), resulting from the increased very low-density lipoprotein (VLDL; 0.21 SD, CI 0.05–0.36) and LDL particle counts (0.17 SD, CI 0.03–0.31). The VLDL increase favoured the increase of VLDL particle size (0.22 SD, CI 0.03–0.41). The apolipoprotein A-I (apoA-I) and total HDL particle counts did not change markedly. However, it is uncertain whether small HDL subclass is affected by menopause (0.19 SD, CI -0.01 to 0.40). From the lipid measurements, cholesterol concentrations in all apoB-containing lipoprotein classes increased from 0.17 to 0.20 SD. The increase in VLDL triglyceride (0.25 SD, CI 0.05–0.45) and HDL triglyceride concentrations (0.24 SD, CI 0.02–

0.46) was even more pronounced. Total serum fatty acid concentration did not change but the fatty acid profile shifted from polyunsaturated to saturated direction. As for the other metabolites, citrate concentration decreased by -0.36 SD (CI -0.57 to -0.14) and glycerol concentration increased by 0.32 SD (CI 0.07–0.58). Glutamine concentration decreased by -0.46 SD (CI -0.72 to -0.20) and leucine concentration increased by 0.25 SD (CI 0.02–0.49). Acetoacetate and 3-hydroxybutyrate levels decreased by -0.44 SD (CI -0.72 to -0.15) and -0.46 (CI -0.75 to -0.17), respectively. When body fat percentage was included as a covariate, the association sizes of lipoprotein, lipid, glycerol and amino acid concentrations were roughly 0.03–0.05 SD smaller (**Result Supplement Table 3**). The adjustment had a negligible effect on the associations of menopause with citrate and ketone levels.

Menopausal hormonal shift and metabolite changes

The menopausal hormonal shift directly explained the change in 64 of the 85 metabolites identified as menopause-responsive in the primary analysis, with effect sizes ranging from 2.1% to 11.2% (**Result Supplement Table 4**). Based on the size of the standardised regression estimates of the two hormones included in the model, the decline of E2 levels had more impact on the results than the increased FSH levels. The hormonal shift was not associated with indirect metabolite changes since the shift was not associated with body fat percentage change.

The key findings are summarised in **Fig. 3**. The menopausal hormonal shift directly explained the concentration increase in apoB (7.4%), LDL particles (8.5%) and LDL cholesterol (10.6%). The effect sizes concerning the total VLDL particle count (4.0%) and triglyceride levels (2.9%) were more modest. Even though the association of menopause and

the increased small HDL particle count was inconclusive in the primary analysis, the exploratory analysis strongly linked them with an effect size of 10.9%.

From the results concerning the association of non-lipoprotein and lipid with menopause in the primary analysis, a direct association with the hormonal shift was confirmed for glutamine (2.4%), citrate (5.0%), 3-hydroxybutyrate (4.4%) and acetoacetate (3.4%) concentrations. The largest effect size of the hormonal shift was found for tyrosine concentration (7.8%), although menopause and tyrosine level association did not remain statistically significant in the primary analysis after multiple comparison corrections.

MHT and metabolite changes

In **Results Supplement Table 2**, the absolute metabolite concentrations for MHT starters during the study including the unstandardised change scores are presented. MHT initiation during follow-up was characterised by a decreased apoB/apoA-I ratio (**Result Supplement Table 5**; the key statistically significant findings are summarised in **Table 2**), resulting from the increased particle count in medium and large HDL subclasses and the decreased small and medium LDL subclass particle counts. VLDL was less affected by MHT than LDL and HDL. As for non-lipid metabolites, we found an inverse association between MHT and glycine concentration. Adjusting for body fat percentage did not influence these associations.

Discussion

This study investigated the associations of menopause and circulating metabolome in 183 women transitioning from perimenopause to early postmenopause. The study also explored whether the menopausal hormonal shift explains the observed changes and whether MHT

initiated during the follow-up ($n = 35$) was associated with metabolite changes. The results showed that menopause-induced hormonal shift is associated with a proatherogenic metabolomic fingerprint. MHT specifically influences LDL, HDL and glycine metabolism. These findings broadly agree with earlier metabolomics studies on menopause,^{15,16} and now connect the previous and present observations to the female sex hormone levels.

Menopause modulates lipoprotein and lipid metabolism towards a proatherogenic profile

ApoB-containing lipoproteins cause ACVD,²¹ with LDL being the primary disease driver.²² Studies using both clinical methods and metabolomics have identified LDL as one of the most menopause-responsive biomarkers.^{8,9,15,16} In agreement with this, we report increased apoB and LDL cholesterol and particle concentration, 7–10% of which are directly explained by the menopausal hormonal shift. The underlying mechanism is probably the well-established oestrogen-mediated LDL receptor modulation,^{23,24} influencing LDL clearance from the circulation.²⁵ However, similar to Auro et al.¹⁵ but contrary to Wang et al.,¹⁶ menopause did not alter LDL size distribution in our study. MHT was associated with decreased particle counts in medium and small LDL subclasses, providing further evidence that female sex hormones regulate LDL metabolism. These observations support the clinical guidelines to initiate MHT early into menopause as this timing offers the greatest cardioprotective benefits.⁴

Triglyceride-rich lipoproteins also contribute to the ACVD risk.²⁶ Menopause was associated with an increased VLDL particle count, favouring larger particles possibly in the range of VLDL1 size. Moreover, VLDL triglyceride and cholesterol concentrations increased. The observed pattern was similar to the results of Auro et al.¹⁵ but different from

Wang et al.¹⁶ Our findings also agree with a recent study²⁷ on the sex differences in plasma metabolites at multiple life stages that identified VLDL triglycerides as the most menopause-responsive lipid measurement.

The menopause and VLDL associations observed in this study were robust against body fat percentage adjustment. Still, only ~4% of the VLDL changes were directly explained by the menopausal hormonal shift. Therefore, the potential causal pathway between menopause and VLDL increase probably entails mediators like insulin resistance, as overproduction of VLDL particles and hypertriglyceridemia are hallmarks of chronically elevated insulin levels.²⁶ VLDL was less affected by MHT than the LDL variables, possibly resulting from the effect on the liver caused by the use of oral products (the majority of MHT starters in this study).²⁵

Unlike apoB-containing lipoproteins, total HDL particle and cholesterol concentrations are associated with reduced ACVD risk in observational studies, but their causal role is debatable.²⁸ Consistent with previous metabolomic studies,^{15,16} the apoA-I count and the HDL particle or cholesterol concentrations did not decrease during follow-up. However, in our previous study,⁷ using data obtained with clinical immunoassay from the same serum samples, HDL cholesterol levels increased. HDL cholesterol increase was also observed during a 4-year follow-up in premenopausal women transitioning into postmenopause.¹⁰ This discrepancy could result from the different measurement methods.

However, based on the present metabolomics analyses, the effects of menopause on HDL metabolism do not favour cardiovascular health. First, menopause was associated with increased HDL triglyceride concentration that, contrary to HDL cholesterol levels, is associated with a higher risk of coronary heart disease.²⁹ Furthermore, the menopausal hormonal shift was associated with a particle count increase in the small HDL

subclass, whereas MHT was associated with a particle count increase in medium and large HDL subclasses. HDL subclasses relate differently to ACVD risk as only larger particles are protective.³⁰ Moreover, HDL size distribution is linked to insulin resistance as smaller particles accumulate when glucose tolerance worsens.³¹ Our results agree with the longitudinal The Study of Women's Health Across the Nation (SWAN) study, where menopause was associated with an increase in the small HDL particle and HDL triglyceride concentrations.³² In the future, examining menopause-associated structural and functional HDL changes will provide more insight into the phenomenon.

Menopause is associated with a metabolic signature indicative of deteriorating insulin sensitivity

Our findings from other metabolite classes link menopause to a broader deterioration of cardiovascular and metabolic health. Blood glucose levels did not increase during follow-up. However, glucose homeostasis is tightly regulated, and insulin sensitivity changes may influence other metabolites more rapidly. For example, menopause was associated with increased glycerol and decreased 3-hydroxybutyrate and acetoacetate concentrations. Glycerol levels are inversely associated with insulin sensitivity and predict type 2 diabetes.³³ Conversely, ketone levels are positively associated with insulin sensitivity in nondiabetic subjects³⁴ like our participants. The menopause-associated decrease in ketone production fits into the picture with the observed VLDL triglyceride increase, indicating that fatty acids are rather esterified into triglycerides than used for oxidation in the liver after menopause.

Moreover, we noticed that the serum fatty acid profile changed from polyunsaturated to saturated, relating to elevated type 2 diabetes risk.³⁵ One explanation for this profile change is increased *de novo* lipogenesis.³⁶ Insulin resistance increases hepatic

fatty acid synthesis, upscaling VLDL production.³⁷ Altered diet is another explanation. Based on the diet assessment, participants' dietary habits were stable during the follow-up. However, this method provides only a crude estimation of the overall diet quality and does not capture possible changes in energy intake.

Furthermore, menopause was associated with amino acid changes, as previously reported.^{15,16,27} Leucine concentration increased during follow-up, and the menopausal hormonal shift was associated with increased tyrosine levels. Elevated aromatic amino acids and branched-chained amino acid concentrations follow insulin resistance^{36,38,39} and predict type 2 diabetes risk.⁴⁰ Higher levels of branched-chained amino acids were associated with higher ACVD risk in women.⁴¹ Conversely, higher glycine and glutamine concentrations predict a decreased risk of type 2 diabetes.^{36,40} In line with our other findings, glutamine concentration decreased during follow-up, contradicting previous observations.^{15,16} Even though ovariectomy in rats did not alter skeletal muscle glutamine synthetase expression or activity,⁴² the glutamine concentration decrease may be due to the reduced branched-chained amino acid catabolism because the primary nitrogen acceptor, α -ketoglutarate, is initially converted to glutamate and, then, partially to glutamine.⁴³ We did not find a statistically significant association between menopause and glycine levels. However, MHT was associated with decreased glycine concentration, similar to previous mass spectrometry studies using randomised controlled trial samples.^{44,45} Therefore, all MHT effects may not favour cardiovascular health.

Menopause-associated changes in the circulating metabolome are linked to bone health but not increased inflammation

Oestrogen receptors exist throughout the body, with menopause causing broad systemic effects on multiple organ systems.⁴⁶ The decreased citrate concentration during follow-up is a notable finding that links the circulating metabolome possibly to the skeletal system, where about 90% of body citrate resides.⁴⁷ In mice, ovariectomy led to bone mineral density loss and decreased bone and plasma citrate levels.⁴⁸ This decrease may result from reduced citrate synthesis due to osteoblast loss and increased citrate consumption by osteoclasts and lipid synthesis.⁴⁹ As menopause relates to a bone mass decrease,⁵⁰ serum citrate concentration could be a novel imaging-free biomarker of bone health in the population. An alternative explanation for the citrate association is that the observed change results from the potential deterioration of insulin sensitivity, as citrate levels were associated with insulin resistance among Finnish bariatric surgery patients.⁵¹ MHT did not influence citrate levels in this study.

Concerning the rest of the quantified metabolites, we found no or inconsistent evidence on their relationship with menopause. Contrary to Wang et al.,¹⁶ we did not observe a positive association between menopause or the menopausal hormonal shift and the inflammation marker GlycA. Moreover, we did not observe an inverse association between MHT and GlycA levels as Auro et al. did.¹⁵ Our findings indicate that at least the short observation time around the final menstrual period (the median follow-up was 14 months) do not reveal a sharp increase in systemic inflammation. Although menopause was previously associated with increased albumin concentration,¹⁶ and MHT users had lower albumin levels than nonusers,¹⁵ neither menopause nor MHT was significantly associated with albumin concentration in this study. Nevertheless, the menopausal hormonal shift was still related to increased albumin levels.

Strengths and limitations

The key strengths of this study are the longitudinal design and the detailed menopausal transition monitoring by repeated hormone measurements. Moreover, we focused on changes occurring around the final menstrual period. Hence, we individualised the follow-up time for each woman to ensure they were at the same early postmenopausal state at the last measurement instead of using a standard follow-up time for all the participants.

The main study limitation is the relatively small sample size for a metabolomics study. This probably led to the detection of the most notable associations only. Additionally, the NMR metabolomics platform focuses on lipoprotein and lipid measurements and does not capture all ACVD-relevant metabolites, such as clotting factors. In the exploratory analysis, we also divided participants into MHT non-starters and starters *post hoc*. We recommend caution when interpreting the findings as women who start MHT may differ from women not requiring medical assistance with menopausal symptoms. Moreover, the whole-body fat percentage was considered the adiposity variable for indirect associations between menopausal hormonal shift and metabolite changes. The hormonal shift did not associate with the body fat percentage change and, therefore, the indirect link with metabolite changes was discarded. In this aspect, visceral fat mass quantification might have been more informative. Last, the generalisability of our findings is limited to healthy white women.

In conclusion, menopause is associated with a proatherogenic circulating metabolome change that relates to the induced hormonal shift and is partially modified by MHT. These findings highlight the impact of female sex hormones on women's cardiovascular health.

Acknowledgements

We thank the ERMA women for their participation and the Faculty of Sport and Health Sciences staff for their contribution to the data collection.

Conflict of Interest: none declared.

Data availability

The data underlying this article cannot be shared publicly for the privacy of the participants. The data will be shared on reasonable request to the corresponding author.

Funding

This work was supported by the Academy of Finland [275323 to V.K. and 309504, 314181 and 335249 to E.K.L].

Competing interests

All authors had financial support from the Academy of Finland for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

References

1. Davis SR, Lambrinoudaki I, Lumsden M, Mishra GD, Pal L, Rees M, Santoro N, Simoncini T. Menopause. *Nat Rev Dis Primer* 2015;**1**:15004.
2. Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, Sherman S, Sluss PM, Villiers TJ de, STRAW 10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. *Menopause N Y N* 2012;**19**:387–395.
3. Powers MS, Schenkel L, Darley PE, Good WR, Balestra JC, Place VA. Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17 beta-estradiol: comparison with conventional oral estrogens used for hormone replacement. *Am J Obstet Gynecol* 1985;**152**:1099–1106.
4. Maas AHEM, Rosano G, Cifkova R, Chieffo A, Dijken D van, Hamoda H, Kunadian V, Laan E, Lambrinoudaki I, Maclaran K, Panay N, Stevenson JC, Trotsenburg M van, Collins P. Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists. *Eur Heart J* 2021;**42**:967–984.
5. Zhu D, Chung HF, Dobson AJ, Pandeya N, Giles GG, Bruinsma F, Brunner EJ, Kuh D, Hardy R, Avis NE, Gold EB, Derby CA, Matthews KA, Cade JE, Greenwood DC, Demakakos P, Brown DE, Sievert LL, Anderson D, Hayashi K, Lee JS, Mizunuma H, Tillin T, Simonsen MK, Adami HO, Weiderpass E, Mishra GD. Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data. *Lancet Public Health* Elsevier Limited; 2019;**4**:e553–e564.
6. Bittner V. Menopause, age, and cardiovascular risk: a complex relationship. *J Am Coll Cardiol* 2009;**54**:2374–2375.
7. Karvinen S, Jergenson MJ, Hyvärinen M, Aukee P, Tammelin T, Sipilä S, Kovanen V, Kujala UM, Laakkonen EK. Menopausal Status and Physical Activity Are Independently Associated With Cardiovascular Risk Factors of Healthy Middle-Aged Women: Cross-Sectional and Longitudinal Evidence. *Front Endocrinol* 2019;**10**.
8. Matthews KA, Crawford SL, Chae CU, Everson-Rose SA, Sowers MF, Sternfeld B, Sutton-Tyrrell K. Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition? *J Am Coll Cardiol* 2009;**54**:2366–2373.
9. Do KA, Green A, Guthrie JR, Dudley EC, Burger HG, Dennerstein L. Longitudinal study of risk factors for coronary heart disease across the menopausal transition. *Am J Epidemiol* 2000;**151**:584–593.
10. Hyvärinen M, Juppi H-K, Taskinen S, Karppinen JE, Karvinen S, Tammelin TH, Kovanen V, Aukee P, Kujala UM, Rantalainen T, Sipilä S, Laakkonen EK. Metabolic health, menopause, and physical activity—a 4-year follow-up study. *Int J Obes* 2021;1–11.

11. Carr MC. The emergence of the metabolic syndrome with menopause. *J Clin Endocrinol Metab* 2003;**88**:2404–2411.
12. Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. *Fertil Steril* 2001;**75**:898–915.
13. Mauvais-Jarvis F, Manson JE, Stevenson JC, Fonseca VA. Menopausal Hormone Therapy and Type 2 Diabetes Prevention: Evidence, Mechanisms, and Clinical Implications. *Endocr Rev* 2017;**38**:173–188.
14. Würtz P, Kangas AJ, Soininen P, Lawlor DA, Davey Smith G, Ala-Korpela M. Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Large-Scale Epidemiology: A Primer on -Omic Technologies. *Am J Epidemiol* 2017;**186**:1084–1096.
15. Auro K, Joensuu A, Fischer K, Kettunen J, Salo P, Mattsson H, Niironen M, Kaprio J, Eriksson JG, Lehtimäki T, Raitakari O, Jula A, Tiitinen A, Jauhiainen M, Soininen P, Kangas AJ, Kähönen M, Havulinna AS, Ala-Korpela M, Salomaa V, Metspalu A, Perola M. A metabolic view on menopause and ageing. *Nat Commun* 2014;**5**:4708.
16. Wang Q, Ferreira DLS, Nelson SM, Sattar N, Ala-Korpela M, Lawlor DA. Metabolic characterization of menopause: cross-sectional and longitudinal evidence. *BMC Med* 2018;**16**:17.
17. Kovanen V, Aukee P, Kokko K, Finni T, Tarkka IM, Tammelin T, Kujala UM, Sipilä S, Laakkonen EK. Design and protocol of Estrogenic Regulation of Muscle Apoptosis (ERMA) study with 47 to 55-year-old women's cohort: novel results show menopause-related differences in blood count. *Menopause N Y N* 2018;**25**:1020–1032.
18. Tikkanen E, Jägerroos V, Rodosthenous R, Holmes M, Sattar N, Ala-Korpela M, Jousilahti P, Lundqvist A, Perola M, Salomaa V, Würtz P. Metabolic biomarkers for peripheral artery disease compared with coronary artery disease: Lipoprotein and metabolite profiling of 31,657 individuals from five prospective cohorts. *medRxiv Cold Spring Harbor Laboratory Press*; 2020;2020.07.24.20158675.
19. Kujala UM, Kaprio J, Sarna S, Koskenvuo M. Relationship of leisure-time physical activity and mortality: the Finnish twin cohort. *JAMA* 1998;**279**:440–444.
20. Masip G, Keski-Rahkonen A, Pietiläinen KH, Kujala UM, Rottensteiner M, Väisänen K, Kaprio J, Bogl LH. Development of a Food-Based Diet Quality Score from a Short FFQ and Associations with Obesity Measures, Eating Styles and Nutrient Intakes in Finnish Twins. *Nutrients* 2019;**11**.
21. Ference BA, Kastelein JJP, Ray KK, Ginsberg HN, Chapman MJ, Packard CJ, Laufs U, Oliver-Williams C, Wood AM, Butterworth AS, Angelantonio ED, Danesh J, Nicholls SJ, Bhatt DL, Sabatine MS, Catapano AL. Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease. *JAMA American Medical Association*; 2019;**321**:364–373.
22. Borén J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, Daemen MJ, Demer LL, Hegele RA, Nicholls SJ, Nordestgaard BG, Watts GF, Bruckert E, Fazio S, Ference BA, Graham I, Horton JD, Landmesser U, Laufs U, Masana L, Pasterkamp G,

- 1 Raal FJ, Ray KK, Schunkert H, Taskinen M-R, Sluis B van de, Wiklund O, Tokgozoglu
2 L, Catapano AL, Ginsberg HN. Low-density lipoproteins cause atherosclerotic
3 cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus
4 statement from the European Atherosclerosis Society Consensus Panel. *Eur Heart J*
5 2020;**41**:2313–2330.
- 6 23. Parini P, Angelin B, Rudling M. Importance of estrogen receptors in hepatic LDL
7 receptor regulation. *Arterioscler Thromb Vasc Biol* 1997;**17**:1800–1805.
- 8 24. Karjalainen A, Heikkinen J, Savolainen MJ, Bäckström AC, Kesäniemi YA. Mechanisms
9 regulating LDL metabolism in subjects on peroral and transdermal estrogen replacement
10 therapy. *Arterioscler Thromb Vasc Biol* 2000;**20**:1101–1106.
- 11 25. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnika V, Sacks FM. Effects of
12 postmenopausal estrogen replacement on the concentrations and metabolism of plasma
13 lipoproteins. *N Engl J Med* 1991;**325**:1196–1204.
- 14 26. Ginsberg HN, Packard CJ, Chapman MJ, Borén J, Aguilar-Salinas CA, Aversa M,
15 Ference BA, Gaudet D, Hegele RA, Kersten S, Lewis GF, Lichtenstein AH, Moulin P,
16 Nordestgaard BG, Remaley AT, Staels B, Stroes ESG, Taskinen M-R, Tokgozoglu LS,
17 Tybjaerg-Hansen A, Stock JK, Catapano AL. Triglyceride-rich lipoproteins and their
18 remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging
19 therapeutic strategies-a consensus statement from the European Atherosclerosis Society.
20 *Eur Heart J* 2021;ehab551.
- 21 27. Bell JA, Santos Ferreira DL, Fraser A, Soares ALG, Howe LD, Lawlor DA, Carslake D,
22 Davey Smith G, O’Keeffe LM. Sex differences in systemic metabolites at four life
23 stages: cohort study with repeated metabolomics. *BMC Med* 2021;**19**:58.
- 24 28. Rosenson RS, Brewer HB, Barter PJ, Björkegren JLM, Chapman MJ, Gaudet D, Kim
25 DS, Niesor E, Rye K-A, Sacks FM, Tardif J-C, Hegele RA. HDL and atherosclerotic
26 cardiovascular disease: genetic insights into complex biology. *Nat Rev Cardiol*
27 2018;**15**:9–19.
- 28 29. Kettunen J, Holmes MV, Allara E, Anufrieva O, Ohukainen P, Oliver-Williams C, Wang
29 Q, Tillin T, Hughes AD, Kähönen M, Lehtimäki T, Viikari J, Raitakari OT, Salomaa V,
30 Järvelin M-R, Perola M, Davey Smith G, Chaturvedi N, Danesh J, Di Angelantonio E,
31 Butterworth AS, Ala-Korpela M. Lipoprotein signatures of cholesteryl ester transfer
32 protein and HMG-CoA reductase inhibition. *PLoS Biol* 2019;**17**:e3000572.
- 33 30. Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM. Lipoprotein particle
34 profiles by nuclear magnetic resonance compared with standard lipids and
35 apolipoproteins in predicting incident cardiovascular disease in women. *Circulation*
36 2009;**119**:931–939.
- 37 31. Wang J, Stančáková A, Soininen P, Kangas AJ, Paananen J, Kuusisto J, Ala-Korpela M,
38 Laakso M. Lipoprotein subclass profiles in individuals with varying degrees of glucose
39 tolerance: a population-based study of 9399 Finnish men. *J Intern Med* 2012;**272**:562–
40 572.

32. El Khoudary SR, Chen X, Nasr A, Billheimer J, Brooks MM, McConnell D, Orchard TJ, Crawford SL, Matthews KA, Rader DJ. HDL (High-Density Lipoprotein) Subclasses, Lipid Content, and Function Trajectories Across the Menopause Transition: SWAN-HDL Study. *Arterioscler Thromb Vasc Biol* 2021;**41**:951–961.
33. Mahendran Y, Cederberg H, Vangipurapu J, Kangas AJ, Soininen P, Kuusisto J, Uusitupa M, Ala-Korpela M, Laakso M. Glycerol and Fatty Acids in Serum Predict the Development of Hyperglycemia and Type 2 Diabetes in Finnish Men. *Diabetes Care* 2013;**36**:3732–3738.
34. Mahendran Y, Vangipurapu J, Cederberg H, Stancáková A, Pihlajamäki J, Soininen P, Kangas AJ, Paananen J, Civelek M, Saleem NK, Pajukanta P, Lusi AJ, Bonnycastle LL, Morken MA, Collins FS, Mohlke KL, Boehnke M, Ala-Korpela M, Kuusisto J, Laakso M. Association of ketone body levels with hyperglycemia and type 2 diabetes in 9,398 Finnish men. *Diabetes* 2013;**62**:3618–3626.
35. Rhee EP, Cheng S, Larson MG, Walford GA, Lewis GD, McCabe E, Yang E, Farrell L, Fox CS, O'Donnell CJ, Carr SA, Vasan RS, Florez JC, Clish CB, Wang TJ, Gerszten RE. Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. *J Clin Invest* 2011;**121**:1402–1411.
36. Roberts LD, Koulman A, Griffin JL. Towards metabolic biomarkers of insulin resistance and type 2 diabetes: progress from the metabolome. *Lancet Diabetes Endocrinol* 2014;**2**:65–75.
37. Smith GI, Shankaran M, Yoshino M, Schweitzer GG, Chondronikola M, Beals JW, Okunade AL, Patterson BW, Nyangau E, Field T, Sirlin CB, Talukdar S, Hellerstein MK, Klein S. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. *J Clin Invest* **130**:1453–1460.
38. Mahendran Y, Jonsson A, Have CT, Allin KH, Witte DR, Jørgensen ME, Grarup N, Pedersen O, Kilpeläinen TO, Hansen T. Genetic evidence of a causal effect of insulin resistance on branched-chain amino acid levels. *Diabetologia* 2017;**60**:873–878.
39. Wang Q, Holmes MV, Davey Smith G, Ala-Korpela M. Genetic Support for a Causal Role of Insulin Resistance on Circulating Branched-Chain Amino Acids and Inflammation. *Diabetes Care* 2017;**40**:1779–1786.
40. Guasch-Ferré M, Hruby A, Toledo E, Clish CB, Martínez-González MA, Salas-Salvadó J, Hu FB. Metabolomics in Prediabetes and Diabetes: A Systematic Review and Meta-analysis. *Diabetes Care* 2016;**39**:833–846.
41. Tobias DK, Lawler PR, Harada PH, Demler OV, Ridker PM, Manson JE, Cheng S, Mora S. Circulating Branched-Chain Amino Acids and Incident Cardiovascular Disease in a Prospective Cohort of US Women. *Circ Genomic Precis Med* 2018;**11**:e002157.
42. Verdier L, Boirie Y, Van Driessche S, Mignon M, Begue R-J, Meynial-Denis D. Do sex steroids regulate glutamine synthesis with age? *Am J Physiol Endocrinol Metab* 2002;**282**:E215–221.
43. Holeček M. Why Are Branched-Chain Amino Acids Increased in Starvation and Diabetes? *Nutrients* 2020;**12**.

44. Zang H, Moritz T, Norstedt G, Hirschberg AL, Tollet-Egnell P. Effects of oestrogen and testosterone therapy on serum metabolites in postmenopausal women. *Clin Endocrinol (Oxf)* 2012;**77**:288–295.
45. Stevens VL, Wang Y, Carter BD, Gaudet MM, Gapstur SM. Serum metabolomic profiles associated with postmenopausal hormone use. *Metabolomics Off J Metabolomic Soc* 2018;**14**:97.
46. Clegg D, Hevener AL, Moreau KL, Morselli E, Criollo A, Van Pelt RE, Vieira-Potter VJ. Sex Hormones and Cardiometabolic Health: Role of Estrogen and Estrogen Receptors. *Endocrinology* 2017;**158**:1095–1105.
47. Costello LC, Franklin RB. Plasma Citrate Homeostasis: How It Is Regulated; And Its Physiological and Clinical Implications. An Important, But Neglected, Relationship in Medicine. *HSOA J Hum Endocrinol* 2016;**1**.
48. Chen H, Wang Y, Dai H, Tian X, Cui Z-K, Chen Z, Hu L, Song Q, Liu A, Zhang Z, Xiao G, Yang J, Jiang Y, Bai X. Bone and plasma citrate is reduced in osteoporosis. *Bone* 2018;**114**:189–197.
49. Granchi D, Baldini N, Olivieri FM, Caudarella R. Role of Citrate in Pathophysiology and Medical Management of Bone Diseases. *Nutrients* 2019;**11**.
50. Sipilä S, Törmäkangas T, Sillanpää E, Aukee P, Kujala UM, Kovanen V, Laakkonen EK. Muscle and bone mass in middle-aged women: role of menopausal status and physical activity. *J Cachexia Sarcopenia Muscle* 2020;**11**:698–709.
51. Luukkonen PK, Qadri S, Ahlholm N, Porthan K, Männistö V, Sammalkorpi H, Penttilä AK, Hakkarainen A, Lehtimäki TE, Gaggini M, Gastaldelli A, Ala-Korpela M, Orho-Melander M, Arola J, Juuti A, Pihlajamäki J, Hodson L, Yki-Järvinen H. Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease. *J Hepatol* 2021;S0168-8278(21)02150-4.

Figure legends

Figure 1. Study flowchart and statistical analysis approach.

Figure 2. The associations of the menopausal transition and key metabolite measurements in women experiencing natural menopause ($n = 183$) adjusted for age at the first measurement, follow-up duration, education level, smoking status, alcohol use, physical activity and diet quality. The figure describes the standardised change (expressed as standard deviation [SD] units) in the metabolite levels during follow-up with respect to the first measurement values, allowing the comparison between metabolite measures with different units and concentrations.

Figure 3. The associations of menopausal hormonal change (the decline in E2 and increase in FSH levels) with key metabolite changes. The colours and their intensity show the association direction and the effect size. The models were adjusted for age at the first measurement, follow-up duration, education level, smoking status, alcohol use, physical activity and diet quality. False discovery corrected P -values: * ≤ 0.05 ; ** ≤ 0.01 . 3-OHB, 3-hydroxybutyrate; Ala, alanine; Gln, glutamine; Gly, glycine; His, histidine; Ile, isoleucine; Leu, leucine; Val, valine; Phe, phenylalanine; Tyr, tyrosine.

1 Text tables

2 Table 1. Characteristics of the participants at the first and last measurements.

	Natural menopause (<i>n</i> = 183)		MHT starters (<i>n</i> = 35)	
	Perimenopause	Postmenopause	Perimenopause	Postmenopause
Age (years)	51.9 (1.9)	53.1 (1.9)	50.6 (1.8)	52.0 (1.9)
Follow-up (days)	-	397 (243–603)	-	464 (334–707)
HT use (days)	-	-	-	220 (191–242)
Sex hormones				
E2 (nmol/l)	0.25 (0.17–0.41)	0.16 (0.11–0.27)	0.25 (0.18–0.42)	0.28 (0.20–0.61)
FSH (IU/l)	30.0 (23.4–48.5)	69.8 (46.8–89.7)	23.0 (16.5–36.1)	36.1 (18.4–60.0)
Education				
Primary	5 (3%)	5 (3%)	1 (3%)	1 (3%)
Secondary	100 (55%)	100 (55%)	15 (43%)	15 (43%)
Tertiary	78 (42%)	78 (43%)	19 (54%)	19 (54%)
Body composition				
Height (cm)	165.1 (5.7)	-	166.3 (5.5)	-
Body mass (kg)	69.5 (11.3)	70.2 (11.6)	70.4 (10.2)	70.5 (10.8)
Body mass index categories				
Healthy weight (< 25 kg/m ²)	92 (50%)	85 (46%)	20 (57%)	19 (54%)
Overweight (25–29.9 kg/m ²)	66 (36%)	71 (39%)	10 (29%)	12 (34%)
Obesity (≥ 30 kg/m ²)	25 (14%)	27 (15%)	5 (14%)	4 (11%)
Percent body fat (%)	30.9 (8.3)	32.1 (8.0)	30.5 (7.1)	31.4 (6.3)
Smoking				
Never	122 (67%)	122 (67%)	26 (74%)	26 (74%)
Quitter	49 (27%)	50 (28%)	6 (17%)	5 (14%)
Smoker	12 (7%)	11 (6%)	3 (9%)	4 (11%)
Alcohol use (portions/week)	3.0 (1.0–5.0)	2.5 (1.0–5.0)	4.5 (2.5–5.8)	2.5 (1.0–4.9)
Diet quality score (0–11)	5.7 (2.3)	5.5 (2.1)	5.5 (2.4)	5.6 (2.4)

Physical activity (MET-h/d)	3.6 (1.7–4.8)	3.8 (2.3–5.6)	4.5 (1.8–7.5)	4.8 (2.5–7.5)
Blood pressure				
Diastolic (mmHg)	85 (10)	82 (10)	80 (9)	77 (11)
Systolic (mmHg)	134 (19)	131 (18)	126 (16)	121 (14)
Diagnosed hypertension	24 (13%)	29 (16%)	4 (11%)	4 (11%)
ATC1 class C medication	25 (14%)	34 (19%)	5 (14%)	6 (17%)
Dyslipidaemia and blood glucose				
LDL cholesterol > 3 mmol/l ^a	99 (54%)	119 (65%)	22 (62%)	20 (57%)
HDL cholesterol < 1.2 mmol/l	5 (3%)	4 (2%)	1 (3%)	0 (0%)
Triglycerides				
Optimal (< 1.2 mmol/l)	123 (67%)	107 (58%)	24 (69%)	24 (69%)
Elevated (> 1.7 mmol/l)	22 (12%)	27 (15%)	1 (3%)	5 (14%)
Fasting glucose > 6 mmol/l	8 (4%)	12 (7%)	2 (6%)	3 (9%)

Data as means (standard deviation), medians (interquartile range) or counts (%).

^a Calculated with Friedewald formula.

E2, 17 β -oestradiol; FSH, follicle-stimulating hormone; MET, metabolic equivalent of task; MHT, menopausal hormone therapy.

1

2

3

4

5

6

7

8

9

Table 2. Menopause and menopausal hormone therapy interactions with key metabolite measurements.

Metabolite	Crude model			Adjusted model ^a		
	Interaction	99.95% CI	P	Interaction	99.95% CI	P
ApoB/apoA-I ratio	-0.54	-0.86 to -0.21	< 0.001	-0.55	-0.88 to -0.22	< 0.001
ApoA-I	0.51	0.08 to 0.93	0.005	0.55	0.13 to 0.97	0.001
Glycine	-0.46	-0.80 to -0.11	0.001	-0.46	-0.80 to -0.12	0.001
Medium HDL particles	0.54	0.10 to 0.97	0.003	0.58	0.15 to 1.01	0.001
Large HDL particles	0.35	0.06 to 0.64	0.004	0.36	0.07 to 0.66	0.002
HDL cholesterol	0.36	0.02 to 0.70	0.028	0.39	0.05 to 0.74	0.008
HDL diameter	0.35	0.05 to 0.65	0.007	0.35	0.04 to 0.74	0.009
Small LDL particles	-0.41	-0.76 to -0.05	0.005	-0.44	-0.83 to -0.05	0.011
LDL particles	0.31	-0.76 to -0.05	0.010	-0.39	-0.75 to -0.03	0.020
Medium LDL particles	-0.39	-0.74 to -0.03	0.017	-0.37	-0.77 to -0.01	0.039

^a age at the first measurement, follow-up duration, education level, and lifestyle factors

Apo, apolipoprotein; HDL, high-density lipoprotein; LDL, low-density lipoprotein

The confidence intervals and P-values were Keff-Šidák-corrected for multiple comparisons.

The Core-ERMA
*longitudinal study over
the menopausal transition*

381 perimenopausal women
started follow-up

234 women
successfully reached **early postmenopause**

Died, $n = 1$
Discontinued, $n = 26$
Inconsistent hormone therapy, $n = 3$
Unclear menopausal status at final
measurements, $n = 48$
Did not reach postmenopause, $n = 69$

Cancer diagnosis, $n = 4$
Lipid- or glucose lowering medication,
 $n = 12$

The Core-ERMA metabolomics, $N = 218$
median follow-up 14 (interquartile range 8 to 20) months

Natural menopause, $n = 183$

**Menopausal hormone therapy
starters, $n = 35$**
• oral, $n = 27$
• transdermal, $n = 8$

Primary analysis
Associations of menopause
and metabolites during
follow-up

Explorative analysis I
Direct and indirect (via body
composition) associations of
menopausal hormonal shift and
metabolite changes

Explorative analysis II
Associations of hormonal
therapy and metabolites
during follow-up

Lipoprotein particles

Lipoprotein particle size

Apolipoproteins

Cholesterols

Triglycerides

Phospholipids

Fatty acid ratios

Glycolysis related metabolites

Amino acids

Ketone bodies

Miscellaneous

-0.6 -0.3 0.0 0.3 0.6
SD change (95% CI)

-0.6 -0.3 0.0 0.3 0.6
SD change (95% CI)

K_{eff} -Šidák-corrected ● $P < 0.05$ ○ $P \geq 0.05$

Lipoprotein particles

Lipoprotein size

Apolipoproteins

Cholesterols

Triglycerides

Phospholipids

Total fatty acids and fatty acid ratios (%)

Miscellaneous

Glycolysis related

Amino acids

Effect size